Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207730> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W4387207730 endingPage "S36" @default.
- W4387207730 startingPage "S36" @default.
- W4387207730 abstract "Stereotactic ablative radiation therapy (SABR) can prolong progression free survival in oligometastatic prostate cancer (omPC) patients. However, predictive tools to identify those who will benefit from SABR are necessary. Our group was the first to demonstrate that plasma levels of prostate cancer-derived extracellular vesicles (ProstEVs) correlate with tumor burden and predict disease progression in omPC after SABR. Herein, we conducted a blinded validation study using plasma samples from the ORIOLE randomized phase 2 clinical trial in castration-sensitive patients.Plasma samples from 46 omPC patients from the Baltimore ORIOLE trial: a 2:1 ratio randomization to SABR vs observation (NCT02680587). Baseline PSMA+ ProstEV levels were measured by standardized and calibrated nanoscale flow cytometry using fluorescent PSMA antibodies. Median ProstEV levels was used as cut-off for low and high levels. Kaplan-Meier curves and Cox regression models were used to determine the association of ProstEV levels with clinical outcomes [PSA progression-free survival (psaPFS) and radiographic distant progression free survival (rPFS)].No association was observed between number of metastatic lesions or baseline PSA and plasma ProstEV levels. The rPFS for patients treated with SABR was 29.6 months. The rPFS for patients treated with SABR with high and low ProstEV levels were 11.1 months and 36 months, respectively (Hazard Ratio: 2.85; 95% CI, 1.01-7.48; P = 0.02). The psaPFS for patients treated with SABR was 11.9 months. The psaPFS for patients with high and low ProstEV levels were 5.9 months and 24.3 months, respectively (HR: 2.44; 95% CI, 1.00-5.94; P = 0.03).ProstEVs is the first blood biomarker of tumor burden that can prognosticate the risk of disease recurrence in omPC patients treated with SABR. While biomarker-guided trials are warranted, our validation study strengthens the clinical value of ProstEVs for personalized radiation therapy." @default.
- W4387207730 created "2023-09-30" @default.
- W4387207730 creator A5008426497 @default.
- W4387207730 creator A5010125684 @default.
- W4387207730 creator A5011710591 @default.
- W4387207730 creator A5025646595 @default.
- W4387207730 creator A5040197178 @default.
- W4387207730 creator A5053901900 @default.
- W4387207730 creator A5070623757 @default.
- W4387207730 creator A5072150761 @default.
- W4387207730 creator A5072545362 @default.
- W4387207730 creator A5072768114 @default.
- W4387207730 date "2023-10-01" @default.
- W4387207730 modified "2023-10-17" @default.
- W4387207730 title "PSMA-Positive Extracellular Vesicles Predict Disease Recurrence in Oligometastatic Castration-Sensitive Prostate Cancer Treated with Stereotactic Ablative Radiotherapy: Analysis of the ORIOLE trial" @default.
- W4387207730 doi "https://doi.org/10.1016/j.ijrobp.2023.06.303" @default.
- W4387207730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784483" @default.
- W4387207730 hasPublicationYear "2023" @default.
- W4387207730 type Work @default.
- W4387207730 citedByCount "0" @default.
- W4387207730 crossrefType "journal-article" @default.
- W4387207730 hasAuthorship W4387207730A5008426497 @default.
- W4387207730 hasAuthorship W4387207730A5010125684 @default.
- W4387207730 hasAuthorship W4387207730A5011710591 @default.
- W4387207730 hasAuthorship W4387207730A5025646595 @default.
- W4387207730 hasAuthorship W4387207730A5040197178 @default.
- W4387207730 hasAuthorship W4387207730A5053901900 @default.
- W4387207730 hasAuthorship W4387207730A5070623757 @default.
- W4387207730 hasAuthorship W4387207730A5072150761 @default.
- W4387207730 hasAuthorship W4387207730A5072545362 @default.
- W4387207730 hasAuthorship W4387207730A5072768114 @default.
- W4387207730 hasConcept C106159729 @default.
- W4387207730 hasConcept C121608353 @default.
- W4387207730 hasConcept C126322002 @default.
- W4387207730 hasConcept C126894567 @default.
- W4387207730 hasConcept C143998085 @default.
- W4387207730 hasConcept C162324750 @default.
- W4387207730 hasConcept C187625094 @default.
- W4387207730 hasConcept C207103383 @default.
- W4387207730 hasConcept C2776235491 @default.
- W4387207730 hasConcept C2776694085 @default.
- W4387207730 hasConcept C2780192828 @default.
- W4387207730 hasConcept C2780739268 @default.
- W4387207730 hasConcept C44249647 @default.
- W4387207730 hasConcept C509974204 @default.
- W4387207730 hasConcept C71924100 @default.
- W4387207730 hasConcept C85393063 @default.
- W4387207730 hasConcept C91602232 @default.
- W4387207730 hasConceptScore W4387207730C106159729 @default.
- W4387207730 hasConceptScore W4387207730C121608353 @default.
- W4387207730 hasConceptScore W4387207730C126322002 @default.
- W4387207730 hasConceptScore W4387207730C126894567 @default.
- W4387207730 hasConceptScore W4387207730C143998085 @default.
- W4387207730 hasConceptScore W4387207730C162324750 @default.
- W4387207730 hasConceptScore W4387207730C187625094 @default.
- W4387207730 hasConceptScore W4387207730C207103383 @default.
- W4387207730 hasConceptScore W4387207730C2776235491 @default.
- W4387207730 hasConceptScore W4387207730C2776694085 @default.
- W4387207730 hasConceptScore W4387207730C2780192828 @default.
- W4387207730 hasConceptScore W4387207730C2780739268 @default.
- W4387207730 hasConceptScore W4387207730C44249647 @default.
- W4387207730 hasConceptScore W4387207730C509974204 @default.
- W4387207730 hasConceptScore W4387207730C71924100 @default.
- W4387207730 hasConceptScore W4387207730C85393063 @default.
- W4387207730 hasConceptScore W4387207730C91602232 @default.
- W4387207730 hasIssue "2" @default.
- W4387207730 hasLocation W43872077301 @default.
- W4387207730 hasLocation W43872077302 @default.
- W4387207730 hasOpenAccess W4387207730 @default.
- W4387207730 hasPrimaryLocation W43872077301 @default.
- W4387207730 hasRelatedWork W1980188241 @default.
- W4387207730 hasRelatedWork W1980245127 @default.
- W4387207730 hasRelatedWork W2038565121 @default.
- W4387207730 hasRelatedWork W2127440557 @default.
- W4387207730 hasRelatedWork W2371104354 @default.
- W4387207730 hasRelatedWork W2372081072 @default.
- W4387207730 hasRelatedWork W2590008096 @default.
- W4387207730 hasRelatedWork W2897445903 @default.
- W4387207730 hasRelatedWork W3082324229 @default.
- W4387207730 hasRelatedWork W3129209394 @default.
- W4387207730 hasVolume "117" @default.
- W4387207730 isParatext "false" @default.
- W4387207730 isRetracted "false" @default.
- W4387207730 workType "article" @default.